The story of Sildenafil presents a intricate picture for investors. While the initial release generated massive returns, the lapse of its patent opened the floodgates to off-brand alternatives, dramatically diminishing https://thegreatbookmark.com/story21653860/sildenafil-and-big-pharma-a-precarious-opportunity